Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aubagio

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

- PMLiVE

Sanofi supports Clexane with Spanish VTE apps

The free iPhone, iPad and Android apps are for healthcare professionals

- PMLiVE

Sanofi’s four-strain flu vaccine Vaxigrip under review in EU

Pharma company also launches production of ingredient for malaria drug

Biogen Idec building

Biogen Idec’s Tecfidera approved in US

Green light from FDA closely follows MS drug's European approval

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

Sanofi reception

Sanofi to act as contract manufacturer for Transgene

French biopharma partners with its big pharma compatriot on long-term deal

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

Sanofi reception

Follow-up data suggests long-term benefit of Sanofi’s Lemtrada in MS

Drug has a durable effect on relapse rates and disability progression

Biogen Idec building

Biogen wins extra patent protection for MS drug Tecfidera

Dosing patent provides exclusivity until 2028

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links